- Correspondence to editorial on “Integrated molecular characterization of sarcomatoid hepatocellular carcinoma”
-
Sun RQ, Zhou SL
- KMID: 2567023
- Clin Mol Hepatol.
- 2025 Apr;31(2):e192-e193.
- doi: 10.3350/cmh.2025.0183
-
- CITED
-
- Close
- SHARE
-
- Close
- Genetic insights into sarcomatoid hepatocellular carcinoma: Critical role of ARID2 in pathogenesis and immune feature: Editorial on “Integrated molecular characterization of sarcomatoid hepatocellular carcinoma”
-
Nishida N
- KMID: 2566992
- Clin Mol Hepatol.
- 2025 Apr;31(2):635-639.
- doi: 10.3350/cmh.2025.0071
-
- CITED
-
- Close
- SHARE
-
- Close
- Integrated molecular characterization of sarcomatoid hepatocellular carcinoma
-
Sun RQ, Ye YH, Xu Y, Wang B, Pan SY, Li N, Chen L, Pan JY, Hu ZQ, Fan J, Zhou ZJ, Zhou J, Song CL, Zhou SL
- KMID: 2566968
- Clin Mol Hepatol.
- 2025 Apr;31(2):426-444.
- doi: 10.3350/cmh.2024.0686
Backgrounds/Aims: Sarcomatoid hepatocellular carcinoma (HCC) is a rare histological subtype of HCC characterized by extremely poor prognosis; however, its molecular characterization has not been elucidated. Methods: In this study, we conducted... -
- CITED
-
- Close
- SHARE
-
- Close
- Gut microbiota-mediated gut-liver axis: a breakthrough point for understanding and treating liver cancer
-
Li C, Cai C, Wang C, Chen X, Zhang B, Huang Z
- KMID: 2566964
- Clin Mol Hepatol.
- 2025 Apr;31(2):350-381.
- doi: 10.3350/cmh.2024.0857
The trillions of commensal microorganisms living in the gut lumen profoundly influence the physiology and pathophysiology of the liver through a unique gut-liver axis. Disruptions in the gut microbial communities,... -
- CITED
-
- Close
- SHARE
-
- Close
- Stem cell exosomes: new hope and future potential for relieving liver fibrosis
-
Li L, Liu Y, Wang K, Mo J, Weng Z, Jiang H, Jin C
- KMID: 2566963
- Clin Mol Hepatol.
- 2025 Apr;31(2):333-349.
- doi: 10.3350/cmh.2024.0854
Liver fibrosis is a chronic liver injury resulting from factors like viral hepatitis, autoimmune hepatitis, non-alcoholic steatohepatitis, fatty liver disease, and cholestatic liver disease. Liver transplantation is currently the gold... -
- CITED
-
- Close
- SHARE
-
- Close
- GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in metabolic dysfunction-associated steatohepatitis livers
-
Li YT, Shao WQ, Chen ZM, Ma XC, Yi CH, Tao BR, Zhang B, Ma Y, Zhang G, Zhang R, Geng Y, Lin J, Chen JH
- KMID: 2566967
- Clin Mol Hepatol.
- 2025 Apr;31(2):409-425.
- doi: 10.3350/cmh.2024.0657
Background/Aims: Metabolic dysfunction-associated steatohepatitis (MASH) is a significant risk factor for gallstone formation, but mechanisms underlying MASH-related gallstone formation remain unclear. Golgi membrane protein 1 (GOLM1) participates in hepatic cholesterol... -
- CITED
-
- Close
- SHARE
-
- Close
- Male preference for TERT alterations and HBV integration in young-age HBV-related HCC: implications for sex disparity
-
Kim JS, Kim HS, Tak KY, Han JW, Nam H, Sung PS, Lee SW, Kwon JH, Bae SH, Choi JY, Yoon SK, Jang JW
- KMID: 2566973
- Clin Mol Hepatol.
- 2025 Apr;31(2):509-524.
- doi: 10.3350/cmh.2024.0545
Background/Aims: Hepatocellular carcinoma (HCC) exhibits significant sex disparities in incidence, yet its molecular mechanisms remain unclear. We explored the role of telomerase reverse transcriptase (TERT) genetic alterations and hepatitis B... -
- CITED
-
- Close
- SHARE
-
- Close
- Challenges and innovations in primary sclerosing cholangitis clinical trials: Evaluating HK-660S and the path forward: Editorial on “Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial”
-
Nishad N
- KMID: 2566978
- Clin Mol Hepatol.
- 2025 Apr;31(2):581-583.
- doi: 10.3350/cmh.2024.0942
-
- CITED
-
- Close
- SHARE
-
- Close
- A novel clinical trial for primary sclerosing cholangitis from Asia: All regional endeavors should improve global management of primary sclerosing cholangitis: Editorial on “Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial”
-
Komori A
- KMID: 2566979
- Clin Mol Hepatol.
- 2025 Apr;31(2):584-588.
- doi: 10.3350/cmh.2024.0945
-
- CITED
-
- Close
- SHARE
-
- Close
- Longitudinal profile of plasma pregenomic RNA in patients with chronic hepatitis B infection on long-term nucleoside analogues and its interaction with clinical parameters
-
Mak LY, Anderson M, Stec M, Chung MSH, Wong DKH, Hui RWH, Seto WK, Cloherty G, Yuen MF
- KMID: 2566970
- Clin Mol Hepatol.
- 2025 Apr;31(2):460-473.
- doi: 10.3350/cmh.2024.0724
Backgrounds/Aims: Plasma pregenomic hepatitis B virus RNA (pgRNA) is a novel biomarker in chronic hepatitis B infection (CHB). We aimed to describe the longitudinal profile of pgRNA and factors influencing... -
- CITED
-
- Close
- SHARE
-
- Close
- Prediction of primary biliary cholangitis among health check-up population with anti-mitochondrial M2 antibody positive
-
Li H, Liu S, Wang X, Feng X, Wang S, Zhang Y, Zhang F, Wang L, Xu T, Li Y
- KMID: 2566971
- Clin Mol Hepatol.
- 2025 Apr;31(2):474-488.
- doi: 10.3350/cmh.2024.0416
Backgrounds/Aims: Anti-mitochondrial M2 antibody (AMA-M2) is a specific marker for primary biliary cholangitis (PBC) and it could be also present in non-PBC individuals. Methods: A total of 72,173 Chinese health check-up... -
- CITED
-
- Close
- SHARE
-
- Close
- Targeting TM4SF1 promotes tumor senescence enhancing CD8+ T cell cytotoxic function in hepatocellular carcinoma
-
Zeng W, Liu F, Liu Y, Zhang Z, Hu H, Ning S, Zhang H, Chen X, Liao Z, Zhang Z
- KMID: 2566972
- Clin Mol Hepatol.
- 2025 Apr;31(2):489-508.
- doi: 10.3350/cmh.2024.0934
Background/Aims: Transmembrane 4 L six family member 1 (TM4SF1) is highly expressed and contributes to the progression of various malignancies. However, how it modulates hepatocellular carcinoma (HCC) progression and senescence... -
- CITED
-
- Close
- SHARE
-
- Close
- Reply to correspondence on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023”
-
Park J, Yu SJ
- KMID: 2567034
- Clin Mol Hepatol.
- 2025 Apr;31(2):e221-e223.
- doi: 10.3350/cmh.2025.0226
-
- CITED
-
- Close
- SHARE
-
- Close
- Erratum to ‘Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial’ [Clin Mol Hepatol 2024;30:807-823]
-
Yim SY, Lee SH, Baek SW, Sohn B, Jeong YS, Kang SH, Park K, Park H, Lee SS, Kaseb AO, Park YN, Leem SH, Curran MA, Kim JH, Lee JS
- KMID: 2567001
- Clin Mol Hepatol.
- 2025 Apr;31(2):669-670.
- doi: 10.3350/cmh.2024.0333e
-
- CITED
-
- Close
- SHARE
-
- Close
- Reply to correspondence on “Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C”
-
Liu CH, Chang YP
- KMID: 2567038
- Clin Mol Hepatol.
- 2025 Apr;31(2):e232-e233.
- doi: 10.3350/cmh.2025.0203
-
- CITED
-
- Close
- SHARE
-
- Close
- Reply to correspondence 2 on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”
-
Hwang N, Fang S
- KMID: 2567037
- Clin Mol Hepatol.
- 2025 Apr;31(2):e228-e231.
- doi: 10.3350/cmh.2025.0195
-
- CITED
-
- Close
- SHARE
-
- Close
- Correspondence to editorial on “Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C”
-
Ryu T, Chang Y, Kim SU, Jang JY
- KMID: 2567027
- Clin Mol Hepatol.
- 2025 Apr;31(2):e203-e205.
- doi: 10.3350/cmh.2025.0179
-
- CITED
-
- Close
- SHARE
-
- Close
- Correspondence to editorial on “Prediction of primary biliary cholangitis among health check-up population with anti-mitochondrial M2 antibody positive”
-
Li H, Liu S, Wang X, Wang L, Xu T, Li Y
- KMID: 2567024
- Clin Mol Hepatol.
- 2025 Apr;31(2):e194-e196.
- doi: 10.3350/cmh.2025.0181
-
- CITED
-
- Close
- SHARE
-
- Close
- Letter to the editor on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”
-
Wang W, Xie Y, Xu A
- KMID: 2567007
- Clin Mol Hepatol.
- 2025 Apr;31(2):e143-e144.
- doi: 10.3350/cmh.2025.0140
-
- CITED
-
- Close
- SHARE
-
- Close
- Decreasing systemic inflammation after TIPS: Still hope for the liver: Reply to correspondence on “Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis”
-
Semmler G, Balcar L, Mandorfer M
- KMID: 2567035
- Clin Mol Hepatol.
- 2025 Apr;31(2):e224-e225.
- doi: 10.3350/cmh.2025.0149
-
- CITED
-
- Close
- SHARE
-
- Close
